Aytu Biopharma (AYTU) Net Income towards Common Stockholders Growth (1y) (2011 - 2026)
Powered by 
Analysis
Aytu Biopharma (AYTU) Net Income towards Common Stockholders Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | -0.05% |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | 284.27% |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | -130.19% |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | -19.23% |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -108.13% |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | -91.06% |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 44.59% |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 7.59% |
| 10 | Aytu Biopharma | 22.49 Mn | -4.22 Mn | 7.60 Mn | -240.66% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -240.66% |
| Dec 31, 2025 | -1,414.78% |
| Sep 30, 2025 | 33.31% |
| Jun 30, 2025 | -5,468.92% |
| Mar 31, 2025 | 238.34% |
| Dec 31, 2024 | 435.42% |
| Sep 30, 2024 | 118.15% |
| Jun 30, 2024 | -126.33% |
| Mar 31, 2024 | 59.90% |
| Dec 31, 2023 | 96.41% |
| Sep 30, 2023 | -1,058.35% |
| Jun 30, 2023 | -83.85% |
| Mar 31, 2023 | 86.49% |
| Dec 31, 2022 | 42.04% |
| Sep 30, 2022 | 97.48% |
| Jun 30, 2022 | 137.14% |
| Dec 31, 2021 | -21.24% |
| Sep 30, 2021 | -546.80% |
| Jun 30, 2021 | -132.49% |
| Dec 31, 2020 | -62.51% |